title: [Castration resistant prostate cancer 2011].
abstract: Our understanding of - as well as our approach to - castration resistant prostate cancer is currently undergoing major changes. New drugs like the CYP-17 inhibitor abiraterone have shown that even in the "hormone refractory" stage the progression of prostate cancer is still driven by signaling of the androgen receptor. Changing the term to castration resistant prostate cancer is one consequence of these new insights. Here we give an overview on the current situation of drug development, therapeutic consequences and future trends.
authors: Urologische Klinik Charité, Berlin, Germany. kurt.miller@charite.de
authors: K
authors: K
authors: Miller
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000736:Androstenes; D000737:Androstenols / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007654:Ketoconazole / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000628:therapy*; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000628:therapy*; D011944:Receptors, Androgen / Q000187:drug effects*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use; D014020:Tissue Extracts / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D011944:Receptors, Androgen; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; C552428:cabazitaxel; C511774:sipuleucel-T; D013254:Steroid 17-alpha-Hydroxylase; D017430:Prostate-Specific Antigen; C089740:abiraterone; D007654:Ketoconazole